OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. (OCGN) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 11 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.6) | C+ (2.5) | D (1.5) | D+ (1.5) | C+ (2.6) | C- (2.1) |
| 2026-11-06 | C+ (2.7) | C- (2.0) | D- (0.8) | D+ (1.7) | C+ (2.7) | C- (2.0) |
| 2026-10-30 | C+ (2.7) | C- (1.9) | D (1.4) | D (1.4) | C+ (2.7) | C- (2.0) |
| 2026-10-23 | C+ (2.7) | C- (1.9) | D (1.4) | D (1.4) | C+ (2.6) | C- (2.0) |
| 2026-10-16 | C+ (2.7) | C- (1.9) | D (1.4) | D (1.2) | C+ (2.6) | C- (2.0) |